CNP-104
- Generic Name
- CNP-104
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis
Phase 1
Active, not recruiting
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- COUR Pharmaceutical Development Company, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05104853
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸OM Research, Lancaster, California, United States
🇺🇸University of California Davis Health, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath